HIF-1α、VEGF及MMP-9在非小细胞肺癌组织中的表达及其意义

doi:10.3969/j.issn.1671-7171.2017.09.007

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the expression of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC) and explore their clinical applications.【Methods】The expression of HIF-1α, VEGF and MMP-9 was measured by immunohistochemistry in 91 cases of NSCLC and corresponding adjacent normal tissues. The relationship between these three factors and the clinicopathological parameters of NSCLC was analyzed.【Results】The expression of HIF-1α, VEGF and MMP-9 in cancer tissue of NSCLC was higher than that in adjacent normal tissues (P＜0.05). The positive rates of HIF-1α, VEGF and MMP-9 in low differentiated NSCLC were higher than those in moderate and highly differentiated NSCLC (P＜0.05). The positive rates of HIF-1α, VEGF and MMP-9 in Ⅲ~Ⅳ stage were higher than those in Ⅰ~Ⅱ stage (P＜0.05). The positive rates of HIF-1α, VEGF and MMP-9 in NSCLC with lymph node metastasis were higher than those in non-lymph node metastasis (P＜0.05). The expression of HIF-1α, VEGF and MMP-9 in NSCLC tissue was not correlated with age, sex, tumor diameter and pathological type. The positive expression of HIF-1α, VEGF and MMP-9 in NSCLC was positively related with one another (P＜0.05).【Conclusion】HIF-1α, VEGF and MMP-9 promoted the occurrence and development of NSCLC; the combined detection of these three factors may provide a more valuable prognosis evaluation and target therapy of NSCLC.

Key words： Hypoxia-Inducible Factor 1, alpha Subunit Vascular Endothelial Growth Factor A Matrix Metalloproteinase 9 Carcinoma, Non-Small-Cell Lung/PA Prognosis

Received: 16 March 2017

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2017.09.007 OR http://www.jcr.net.cn/EN/Y2017/V34/I9/1687

[1]唐金明,李旭,谢李,等.ⅢA(N2)期非小细胞肺癌的诊疗进展[J].医学临床研究,2015,32(12):2414-2422.
[2]刘贤忠,张丽婷,童卫泉,等.肺癌侵袭和转移分子机制研究进展[J].中国医学科学院学报,2016,38(1):108-112.
[3]郭树鹏,杨柳,张莉琳,等.HIF-1α信号通路在肿瘤细胞调控中的研究进展[J].现代生物医学进展,2015,15(16):3145-3148.
[4]刘登辉,刘红光.HIF-1α和VEGF在乳腺癌中作用的研究进展[J].肿瘤药学,2013,3(1):7-12.
[5]刘天怡,李佩玲.基质金属蛋白酶-9及其相关因子与卵巢癌的研究进展[J].现代肿瘤医学,2015,23(8):1159-1162.
[6]王晓敏,任力,岳颖,等.EGFR、VEGF和nm23在非小细胞肺癌中的表达及临床意义[J].诊断病理学杂志,2013,20(4):239-242.
[7]王明正,白峰,刘佳坤,等.CXCR4、VEGF在非小细胞肺癌组织中的表达及意义[J].现代肿瘤医学,2013,21(9):1989-1992.
[8]聂弘,高从荣,赵敏,等.HIF-1α、Survivin在非小细胞肺癌中的表达[J].安徽医科大学学报,2015,50(11):1674-1676.
[9]杨世疆,朱志军,薛亚军,等.非小细胞肺癌癌组织HIF-1α及MMP表达研究[J].中华全科医学,2013,11(4):513-566.
[10]覃玲艳,王华新,郭凌川,等.CD147、EGFR和HIF-1α在非小细胞肺癌中的表达及意义[J].江苏医药,2016,42(4):423-427.
[11]梁乃超.MMP-9和VEGF在非小细胞肺癌患者中的表达情况[J].医学综述,2017,23(9):1867-1869.
[12]曾敏,徐利强,严会志,等.血管内皮生长因子(VEGF)在非小细胞肺癌中的表达及其与临床病理特征的相关性[J].现代肿瘤医学,2016,24(21):3386-3389.
[13]袁义,王娟.非小细胞肺癌组织MMP9、EGFR的表达及意义[J].临床肺科杂志,2013,18(9):1628-1630.
[14]Zhang XD,Wu Q,Yang SH.Effects of siRNA-mediated HIF-1alpha gene silencing on angiogenesis in osteosarcoma[J].Pak J Med Sci,2017,33(2):341-346.
[15]Tsai SH,Huang PH,Hsu YJ,et al.Inhibition of hypoxia inducible factor-1alpha attenuates abdominal aortic aneurysm progression through the down-regulation of matrix metalloproteinases[J].Sci Rep,2016,6:28612.